Study flowchart.

<p>Study flowchart.</p

Influenza strains distribution among main study groups.

<p>Influenza strains distribution among main study groups.</p

Impact of influenza-positive virological samples on final disposition decision.

<p>Impact of influenza-positive virological samples on final disposition decision.</p

Frequency of severity criteria as a function of influenza results.

<p>Frequency of severity criteria as a function of influenza results.</p

The main characteristics of the study groups.

<p>The main characteristics of the study groups.</p

Dose response curves for cenicriviroc-dependent inhibition (A) and maraviroc-dependent inhibition (B).

<p>R5, dual and X4-tropic HIV-2 strains are depicted in continuous, dashed and dotted black lines, respectively. HIV-1 R5-tropic strain is depicted using the continuous gray line.</p

Baseline characteristics of the 116 patients.

<p>ART: antiretroviral therapy, ATV: atazanavir, DRV: darunavir, EFV: efavirenz, ETR: etravirine, FTC: emtricitabine, IQR: interquartile range, LPV: lopinavir, MVC: maraviroc, NNRTI: non nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors, NVP: nevirapine, PI: protease inhibitors, RAL: raltegravir, TDF: tenofovir, /r: boosted with ritonavir.</p><p>Baseline characteristics of the 116 patients.</p

Distribution of plasma HIV-1 viral load at baseline (BL), Week (W)12, W24, W36, W48, W72 and W96.

<p>Distribution of plasma HIV-1 viral load at baseline (BL), Week (W)12, W24, W36, W48, W72 and W96.</p

Distribution of NRTI (a) and NNRTI (b) resistance-associated mutations detected in the historical genotypic resistance tests of the patients.

<p>NNRTI: non nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors.</p

Distribution of tenofovir, emtricitabine and rilpivirine plasma concentrations at different time-points.

<p>Distribution of tenofovir, emtricitabine and rilpivirine plasma concentrations at different time-points.</p